Polyplus-transfection promises solution to gene therapy manufacturing woes

6 April 2020
polyplus_large

French company Polyplus-transfection is about to launch a new reagent that has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.

The transfection reagent FectoVIR-AAV will be available from next month, and it is hoped that it will help to tackle the significant and well-identified bottleneck in manufacturing sufficient amounts of AAV viral vectors to treat patients.

"This will alleviate a major concern for the gene therapy sector"This manufacturing need will grow more intense as further gene therapies are commercialized, and reach late-stage clinical trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology